Global $16.4B Colorectal Cancer Drugs Market Outlook, 2026 - Diagnosed Incident Cases Expected to Increase by 27.3%, to 672,400 Cases by 2037

DUBLIN, July 12, 2022 /PRNewswire/ --  The "Colorectal Cancer Drugs Global Market Report 2022, Type, Distribution Channels, Class" report has been added to ResearchAndMarkets.com's offering.

The global colorectal cancer drugs market is expected to grow from $12.77 billion in 2021 to $13.6 billion in 2022 at a compound annual growth rate (CAGR) of 6.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $16.43 billion in 2026 at a CAGR of 4.9%.

North America was the largest region in the colorectal cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The number of colorectal cancer worldwide has been increasing. According to the American Cancer Society (ACS), there were around 101,420 new cases of colon cancer and around 44,180 new cases of rectal cancer registered in the USA in 2019. The diagnosed incident cases of colorectal cancer are expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as low-fiber diet, obesity, consumption of alcohol and tobacco amongst others. The increase in number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.

Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies. 

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body's immune system to fight cancer rather than chemical drugs which reduces the body's immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

Report Scope

Where is the largest and fastest growing market for the colorectal cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The Market Characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
• Market segmentations break down market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

 Companies Mentioned

• Merck & Co. Inc.
• Roche
• Sanofi
• Amgen
• Pfizer Inc.
• Abbott Laboratories
• Taiho Pharma
• Novartis
• GlaxoSmithKline
• Onyx
• TAKEDA PHARMACEUTICALS
• Bristol-Myers Squib
• Sumitomo Dainippon Pharma
• Array BioPharma
• Eli Lilly
• RANDOX LABORATORIES
• Suzhou Zelgen Biopharmaceuticals
• Beckman Coulter Inc.
• Regeneron
• EDP Biotech
• Genomic Tree
• Metabiomics Corporation
• SIEMENS HEALTHCARE
• Suzhou Zelgen Biopharmaceuticals
• Sumitomo Dainippon Pharma
• EPIGENOMICS

For more information about this report visit https://www.researchandmarkets.com/r/n1hpkw

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets